Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03834948 · ClinicalTrials.gov registry record · Phase 1
AO-176 in Multiple Solid Tumor Malignancies
A Phase 1 study of Solid Tumor, sponsored by Arch Oncology.
- Completed
- Registry status
- Phase 1
- Development phase
- 57
- Enrollment target
- 10
- Study locations
NCT03834948 is a Phase 1 study of Solid Tumor that has completed, run by Arch Oncology. The registered enrollment target is 57 participants, below the 221-participant average among 196 other Solid Tumor trials with a reported enrollment target (74% lower). The trial reports 10 study locations across 8 states.
The verdict
NCT03834948, a Phase 1 study of Solid Tumor, has completed, sponsored by Arch Oncology.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 57 participants
- Enrollment target
- 10
- Study locations
Study Summary
This is a first-in-human, Phase 1/2 multi-center, open-label, dose escalation and expansion study of AO-176 which will evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and clinical effects of AO-176 in patients with advanced solid tumors.
Conditions Studied
Interventions
- DRUG AO-176
- DRUG AO-176 + Paclitaxel
- DRUG AO-176 + Pembrolizumab
Study Locations (10)
California
- University of Southern California - Los Angeles
- University of California San Francisco - San Francisco
Virginia
- University of Virginia - Charlottesville
- Virginia Cancer Specialists - Fairfax
Massachusetts
- Dana-Farber Cancer Institute - Boston
Oklahoma
- Oklahoma University, Stephenson Cancer Center - Oklahoma City
Oregon
- Oregon Health Science University - Portland
Pennsylvania
- Sidney Kimmel Cancer Center, Thomas Jefferson University - Philadelphia
Tennessee
- Tennessee Oncology - Nashville
Washington
- Northwest Medical Specialties - Tacoma
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 57 participants |
| Start Date | 2019-02-04 |
| Est. Completion | 2023-02-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03834948
The ClinicalTrials.gov registry entry for NCT03834948 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 57 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 221-participant average among 196 other Solid Tumor trials with a reported enrollment target (74% lower). The listed sponsor is Arch Oncology, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Solid Tumor appearing as the primary indexed condition, and to 3 interventions - of which AO-176 is the first listed.
NCT03834948 reports 10 study locations spanning 8 distinct geographic areas - top geographies include California, Virginia, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT03834948 about?
NCT03834948 is a clinical study titled "AO-176 in Multiple Solid Tumor Malignancies". This is a first-in-human, Phase 1/2 multi-center, open-label, dose escalation and expansion study of AO-176 which will evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and clinical effects of AO-176 in patients with advanced solid tumors.
What is the current status of trial NCT03834948?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 57 participants. The study started on 2019-02-04. Estimated completion is 2023-02-15.
What conditions does trial NCT03834948 study?
This clinical trial studies the following conditions: Solid Tumor.
What interventions are being tested in trial NCT03834948?
The interventions under investigation include: AO-176 (DRUG), AO-176 + Paclitaxel (DRUG), AO-176 + Pembrolizumab (DRUG).
Who is sponsoring clinical trial NCT03834948?
This trial is sponsored by Arch Oncology, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03834948 being conducted?
This trial has 10 study locations across California, Massachusetts, Oklahoma, Oregon, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Phase I Study of ROSE12 Alone and in Combination With Other Anti-tumor Agents in Patients With Solid Tumors
RECRUITING · Phase 1
-
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
RECRUITING · Phase 1
-
Concurrent Azeliragon With Craniospinal Irradiation
RECRUITING · Phase 1
-
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
RECRUITING · Phase 1
-
A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.